Company Overview

Achieve Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for nicotine addiction and smoking cessation. The company operates within the biopharmaceutical and healthcare industries, with its primary emphasis on central nervous system (CNS) disorders related to addiction. Its core value proposition centers on addressing the significant unmet medical need for effective pharmacological solutions to help smokers quit and prevent relapse.

The company’s primary product candidate is cytisinicline, a plant-based, orally administered small molecule that acts as a partial agonist of the nicotinic acetylcholine receptor. Cytisinicline is being developed as a smoking cessation therapy and is the sole material revenue and value driver. Achieve Life Sciences traces its origins to earlier biotechnology ventures and adopted its current strategic focus after acquiring global rights to cytisinicline and reorganizing as Achieve Life Sciences, Inc., which is publicly traded on Nasdaq under the ticker ACHV.

Business Operations

Achieve Life Sciences operates as a single-segment clinical-stage biopharmaceutical company, generating no commercial product revenue and relying primarily on equity financing to fund operations. Its business activities are centered on clinical development, regulatory strategy, and preparation for potential commercialization of cytisinicline. The company conducts and manages Phase 2 and Phase 3 clinical trials, including large-scale, randomized studies designed to support regulatory approval in the United States.

Operationally, the company relies on third-party contract research organizations (CROs), clinical trial sites, and manufacturers for drug development, testing, and supply. Achieve Life Sciences does not maintain internal manufacturing facilities. The company holds intellectual property rights related to cytisinicline formulations, dosing regimens, and therapeutic use in smoking cessation, which form the core assets underpinning its operations.

Strategic Position & Investments

Achieve Life Sciences’ strategy is narrowly focused on advancing cytisinicline toward regulatory approval and eventual commercialization as a first-in-class or best-in-class smoking cessation therapy. Key strategic priorities include completing late-stage clinical trials, engaging with the U.S. Food and Drug Administration on regulatory pathways, and preparing for potential market entry, either independently or through strategic partnerships.

The company has made targeted investments in clinical development programs rather than broad acquisitions or portfolio diversification. Achieve Life Sciences does not currently report ownership of multiple subsidiaries or a diversified pipeline; its strategic positioning is built around depth in a single therapeutic candidate and indication. Its focus on nicotine addiction places it within an emerging area of CNS therapeutics that intersects public health, behavioral medicine, and pharmaceutical innovation.

Geographic Footprint

Achieve Life Sciences is headquartered in the United States, with corporate operations based in Seattle, Washington. Its clinical development activities are primarily focused on the United States, where the company conducts the majority of its clinical trials and regulatory interactions. This geographic concentration aligns with its near-term objective of obtaining approval from U.S. regulatory authorities.

While the company holds global rights to cytisinicline, it currently has limited direct operational presence outside the United States. International exposure is mainly indirect, through intellectual property coverage and the potential for future licensing or commercialization arrangements in Europe, Asia-Pacific, and other global markets if the product advances successfully.

Leadership & Governance

Achieve Life Sciences is led by an executive team with experience in biotechnology, drug development, and corporate finance. The leadership emphasizes disciplined capital management, regulatory execution, and a focused development strategy centered on a single high-impact therapeutic opportunity. Corporate governance follows U.S. public company standards, with oversight provided by an independent board of directors.

Key executives include:

• John Bencich – Chief Executive Officer
• Cindy Jacobs – President and Chief Medical Officer
• Mark S. Foerderer – Chief Financial Officer
• Judith Mitchel – Chief Regulatory Officer

The leadership team’s strategic vision prioritizes advancing cytisinicline through evidence-based clinical development while maintaining optionality for partnerships or commercialization strategies that maximize shareholder and public health value.